A small study conducted in India has identified a potential epigenetic mechanism associated with triple-negative breast cancer (TNBC), a particularly aggressive subtype of the disease. Researchers from the Indira Gandhi Institute of Medical Sciences in Patna and the All India Institute of Medical Sciences in New Delhi found that a specific gene, TRIM33, was more active in tumor tissues compared to healthy breast tissue from the same patients.
The disease is frequently associated with high rates of recurrence, metastasis, and resistance to standard treatments. While members of the tripartite motif-containing protein family, or TRIM proteins, are known to regulate tumor growth through their roles in cell proliferation, invasion, and migration, the specific role of TRIM33 in TNBC had not been well understood. Previous research indicated that TRIM33 could act as either a tumor suppressor or a tumor promoter depending on the cancer context, partly due to its involvement in TGF-β-related signaling pathways. However, data regarding its expression patterns and epigenetic regulation in Indian patients with TNBC were previously lacking.
To investigate this gap, the research team included twenty-eight patients with histologically confirmed triple-negative breast cancer in their study. Tissue samples were collected at the time of surgery, consisting of the tumor tissue and paired adjacent non-tumor breast tissue from each patient. The study focused on measuring both the mRNA and protein levels of TRIM33, as well as the methylation status of its promoter region.
The researchers employed several laboratory techniques to assess these molecular markers. Western blotting and immunohistochemistry were utilized to detect TRIM33 protein levels, offering insights into the actual protein presence within the tissue. To determine the epigenetic regulation of the gene, methylation-specific PCR, or MS-PCR, was applied to assess the methylation status of the TRIM33 promoter.
The results showed that TRIM33 expression was generally increased in the TNBC tissue compared to the paired adjacent non-tumor tissue. Specifically, increased TRIM33 mRNA expression was observed in 19 of the 28 cases, representing 67.9% of the patients. At the protein level, elevated TRIM33 expression was detected in 16 of the 28 cases, or 57.1%.
An unmethylated or hypomethylated pattern of the TRIM33 promoter was observed in 22 of the 28 cases, accounting for 78.6% of the patients.
The researchers also examined the relationship between TRIM33 expression and the clinicopathological characteristics of the patients. TRIM33 protein expression showed significant associations with several factors, including the clinical stage of the cancer. Similarly, the promoter methylation status was associated with selected clinicopathological parameters. These associations suggest that the level of TRIM33 expression and its epigenetic regulation may be linked to the progression and severity of the disease. However, the study did not establish a causal relationship between TRIM33 hypomethylation and tumor progression, but rather identified a statistical association within the sample.
The study has several limitations that must be considered when interpreting the results. The sample size was relatively small, consisting of only 28 patients, which limits the statistical power and generalizability of the findings. The study was conducted in a specific geographic and demographic context, involving Indian patients, and it is unclear whether these findings would be consistent in other populations. The authors noted that these findings warrant validation in larger patient cohorts to confirm the potential role of epigenetic regulation of TRIM33 in TNBC.
Subject of Research: Epigenetic regulation of TRIM33 in triple-negative breast cancer
Article Title: Promoter hypomethylation associated with elevated TRIM33 expression in triple-negative breast cancer patients
Article References: Chaudhary, A., Kumar, M., Akhtar, M. J., Massey, S., Mohan, L., & Ahmad, M. M. (2026). Promoter hypomethylation associated with elevated TRIM33 expression in triple-negative breast cancer patients. Frontiers in Oncology, 16, Article 1973520. https://doi.org/10.3389/fonc.2026.1973520
Image Credits: AI Generated
DOI: 10.3389/fonc.2026.1973520
Keywords: triple-negative breast cancer, TRIM33, epigenetics, promoter methylation, gene expression, breast cancer research, TNBC, DNA methylation, Promoter, hypomethylation, associated, elevated
News Source: Nathaniel Bowman. (November 9, 2026). TRIM33 Gene Activity Linked to Aggressive Breast Cancer. Scienmag.



